Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a notable player in the biopharmaceutical sector, has recently announced its participation in a series of upcoming investor conferences. This initiative aligns with the company’s ongoing commitment to keeping investors informed about its development pipeline and strategic vision. Set against the backdrop of a rapidly evolving cancer treatment landscape, Zentalis specializes in the advancement of novel therapeutics, including its uniquely positioned WEE1 inhibitor. The company’s WEE1 inhibitor aims to revolutionize treatment approaches for patients suffering from ovarian cancer and other tumor types. As a clinical-stage biopharmaceutical company, Zentalis is ...
Zentalis Pharmaceuticals Grants Inducement Stock Options to New EmployeesZentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for cancer treatment, has recently announced the grant of non-qualified stock options to five newly hired employees. This move comes as a part of the company s efforts to attract and retain top talent in accordance with Nasdaq Listing Rule 5635(c)(4).On July 1, 2024, Zentalis Compensation Committee of the Board of Directors approved the grant of 40,875 shares of the company s common stock to these new employees. These stock options have been offered under the Zentalis Pharmaceuticals, Inc. 2022 Employment In...
New York and San Diego, May 29, 2024 - Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics to combat cancer, is excited to announce the appointment of Dr. Luke Walker to its Board of Directors. Dr. Walker, currently serving as the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck and Co., Inc., brings extensive experience as an oncologist and drug developer in advancing novel cancer therapies.Dr. Walker s appointment to the Board of Directors comes at a pivotal time for Zentalis Pharmaceuticals. The company is dedicated to developing small molecule therapeutics that target fundamental biological p...
: Zentalis Pharmaceuticals has announced promising initial findings from its Phase 1 clinical trial exploring the efficacy and safety of azenosertib in combination with gemcitabine for the treatment of relapsed or refractory osteosarcoma. These results are set to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Osteosarcoma, a highly aggressive form of bone cancer, poses a significant therapeutic challenge, particularly in relapsed or refractory cases where existing treatment options often prove inadequate. Researchers at Zentalis Pharmaceuticals have explored the potential benefits of combining azenosertib, an investigational agent, with gemcitabine, a well-established ...
Sources:
Zentalis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zentalis Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Zentalis Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
